KRAS mutations are the drivers of various cancers, including non–small cell lung cancer,
colon cancer, and pancreatic cancer. Over the last 30 years, immense efforts have been …

Background Immune checkpoint inhibitors are effective cancer treatments, but molecular
determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies …

The search for specificity in cancers has been a holy grail in cancer immunology. Cancer
geneticists have long known that cancers harbor transforming and other mutations …

The mutational repertoire of cancers creates the neoepitopes that make cancers
immunogenic. Here, we introduce two novel tools that identify, with relatively high accuracy …

The present invention relates to the provision of vaccines which are specific for a patient's
tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor …

T cells recognize tumor-derived mutated peptides presented on MHC by tumors. The
recognition of these neo-epitopes leads to rejection of tumors, an event that is critical for …

The development of next generation sequencing technologies has revolutionized our
understanding of how specific genetic events contribute to cancer initiation and progression …

It is well established that the immune system has the capacity to attack malignant cells.
During malignant transformation cells acquire numerous molecular and biochemical …

Introduction Pancreas ductal adenocarcinoma (PDAC) is a frequently lethal malignancy that
poses unique therapeutic challenges. The current mainstay of therapy for metastatic PDAC …

Cancer is a disease caused by DNA mutations. Cancer therapies targeting defined
functional mutations have shown clinical benefit. However, as 95% of the mutations in a …